Showing results (391-400 of 421) with videos related to

Sort By:
Pageof 43
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|May 5, 2016
[Body mass index and the risk of lung cancer incidence in smokers: a prospective cohort study]F Li, S H Xie, G Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|November 5, 2020
[Exploratory research on developing lung cancer risk prediction model in female non-smokers]Z Y Lyu, N Li, S H Chen, et al.
Oncogene|March 21, 2000
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanomaS Ren, M J Smith, I D Louro, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|April 28, 2020
Accuracy of prenatal ultrasound screening to identify fetuses infected by cytomegalovirus which will develop severe long-term sequelaeM Leruez-Ville, S Ren, J-F Magny, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|July 31, 2018
[Alcohol consumption and the risk of lung cancer in males: a prospective cohort study]L P Wei, N Li, G Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|May 11, 2018
[Tea consumption and the risk of lung cancer in Chinese males: a prospective cohort study]X Li, N Li, G Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|March 19, 2020
[Priority setting in scaled-up cancer screening in China: an systematic review of economic evaluation evidences]J F Shi, A Y Mao, Y N Bai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Zhonghua Yi Xue Za Zhi|October 31, 2017
[Relationship between inflammatory markers and the risk of colorectal cancer in Kailuan male cohort]G Wang, W G Xu, F Li, et al.
Pageof 43